Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.
CXC chemokines play an important role in recruitment of T cells to the site of activation and regulation of angiogenesis. CXC chemokines are secreted by T cells stimulated with cytokines or by established cytotoxic T lymphocyte (CTL) lines at recognition of conventional antigen (Ag), but the activation requirements and the relationship of interferon-gamma (IFN-gamma) inducible protein (IP-10) secretion with IFN-gamma induction in lymphocytes are still unclear. We studied the induction of IP-10 from nonadherent peripheral blood mononuclear cells (PBMC) by IFN-gamma, interleukin-12 (IL-12), and the HER-2 peptide E75, which forms a CTL-defined antigen. We found that IFN-gamma alone was a weak inducer of IP-10 in these cells, whereas IL-12 was a significantly stronger inducer of IP-10. In the presence of IL-12, the tumor peptide E75 (HER-2, 369-377) was a stronger inducer of IP-10 than was IL-12 alone. E75 and its variants mutated at position 5 could also induce IP-10 in the absence of exogenous IL-12 or IFN-gamma. IP-10 induction by E75 required HLA-A2 presentation and B7-CD28 interactions and was partially inhibited by blocking of CD40-CD40L interactions. These results indicate that presentation of tumor peptides to peripheral T cells can induce a fast chemokine response, which in its early phase may be higher than the IFN-gamma response. This shows that the IP-10 response was independent of any early-phase IFN-gamma response in peripheral T cells. This may be important for understanding the regulation of the balance between chemoattractant chemokines (CC) and CXC chemokines by tumor Ag and may have implications for understanding the mechanisms of polarization of T cells and conditioning of antigen-presenting cells (APC) by tumor antigens.
Lee
T V
TV
Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Kim
D K
DK
Peoples
G E
GE
Castilleja
A
A
Murray
J L
JL
Gershenson
D M
DM
Ioannides
C G
CG
D001943:Breast Neoplasms / Q000276:immunology*; D023201:CD40 Ligand; D002448:Cell Adhesion / Q000276:immunology; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism*; D015789:HLA-A2 Antigen / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D018664:Interleukin-12 / Q000494:pharmacology; D007700:Kinetics; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000502:physiology; D010446:Peptide Fragments / Q000502:physiology*; D010969:Plastics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology*
D023201:CD40 Ligand; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; D015789:HLA-A2 Antigen; D007371:Interferon-gamma; D018664:Interleukin-12; D008562:Membrane Glycoproteins; D010446:Peptide Fragments; D010969:Plastics; D018719:Erb-b2 Receptor Tyrosine Kinases